Loading…
← CockpitCompetitor Analysis › 3218.TWO Universal Vision Biotechnology Co., Ltd.Open in the cockpit ↗

Universal Vision Biotechnology Co., Ltd.3218.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Medical/Nursing Services
Momentum strong 64
Mkt cap
$309M
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$627,132
20-day average traded
Fwd P/E
9.2×
forward earnings
ROIC−WACC
+18.7 pp
WACC 5.0%
Hurdle
-29 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · TWDNT$122.50
1D-0.4%
1W-2.8%
1M-7.5%
3M-8.6%
6M-3.5%
YTD-16.1%
1Y-14.9%
ATR %2.5%
52w lowhigh23.9% off high

What Universal Vision Biotechnology does

No business profile yet.

Universal Vision Biotechnology at a glance

Size Universal Vision Biotechnology (3218.TWO) is a Taiwan Health Care company (Medical/Nursing Services) with a market value of $309M, the 627th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$122.50 on 18 Nov 2026.

Performance Over six months the shares fell 3.5%, against -4.0% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 4.8% over the last twelve months (peer median +6.0%); the operating margin is 30.8% (peer median 8.0%).

Valuation It trades at 9.2× forward earnings against a peer median of 17.6× (3rd cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -29 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026Peer median 983218.TWO 96
Six months, rebased to 100: Universal Vision Biotechnology against the median of its 20 peers (local-currency closes).

Universal Vision Biotechnology financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$4.41BNT$4.20BNT$4.23BNT$4.08BNT$3.49B
Revenue growth—-1%+4%+17%—
Gross profitNT$2.40BNT$2.34BNT$2.37BNT$2.31BNT$2.02B
EBITDANT$1.94BNT$1.92BNT$1.92BNT$1.76BNT$1.45B
Net incomeNT$1.07BNT$1.04BNT$1.06BNT$1.05BNT$851M
Free cash flowNT$1.54BNT$1.10BNT$1.24BNT$1.08BNT$778M
Capital expenditureNT$458MNT$564MNT$437MNT$474MNT$493M
Total debtNT$1.36BNT$1.06BNT$1.05BNT$964MNT$972M

Quarterly statements and history in the cockpit →

Universal Vision Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%AUNANIOXDRAGARWQ300642AYUPAM129860JSLLIDXACLSRTA127120301060DNAWELLFLGTNEPHROPLUSGMRS3218.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Universal Vision Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×AUNANIOXM129860JSLLIDXACLSRTAWELLNEPHROPLUSGMRS19513218.TWORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Universal Vision Biotechnology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%AUNANIOXDRAGARWQSTLN300642AYUPA9860JSLLACL301060WELLNEPHROPLUSGMRS19513218.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Universal Vision Biotechnology is the large dot.

Universal Vision Biotechnology competitors and peer comparison

How Universal Vision Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Universal Vision Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure3218.TWOPeer medianRank in peer set
1-month return-7.5%-8.8%11th highest of 21
6-month return-3.5%-4.0%10th highest of 20
Distance from 52-week high-23.9%-30.8%10th highest of 21
Revenue growth (TTM)+4.8%+6.0%10th lowest of 21
Operating margin30.8%8.0%2nd highest of 21
Forward P/E9.2×17.6×3rd cheapest of 13
Growth the price implies (Req g, 7 yrs)-13.8%6.6%3rd least demanding of 17
Growth delivered (Del g)+15.4%+16.5%9th highest of 17
Hurdle (Req g minus delivered)-29.2 pp-10.9 pp4th least demanding of 17
ROIC minus cost of capital+18.7 pp-2.5 pp2nd highest of 20
EV / EBITDA5.4×9.8×3rd cheapest of 13
Net debt / EBITDA0.2×1.6×6th least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are Universal Vision Biotechnology's closest peers?
The cockpit's peer set: Auna (AUNA), NIOX (NIOX.L), Dr. Agarwal'S Eye Hospital (DRAGARWQ.NS), Oncology Institute (STLN), Tellgen (300642.SZ), Australian Unity Ltd Pref (AYUPA.AX), M1 Kliniken (M12.DE), ADICON (9860.HK).
Is Universal Vision Biotechnology expensive compared with its peers?
On forward p/e it trades at 9.2× against a peer median of 17.6×, 3rd cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -29 pp: the price already allows for a slowdown.
How has Universal Vision Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -3.5% against -4.0% for the median peer; over one year -14.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.